On July 24, 2025, Calidi Biotherapeutics, Inc. announced the elimination of the President of Medical and Scientific Affairs position, effective July 29, 2025, as part of cost optimization efforts. Additionally, on July 25, 2025, the company proposed a reverse stock split at a 1-for-12 ratio.